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Abstract
Background: The efficacy of operative resection of liver metastasis from colorectal cancer has
been established. However, a treatment for liver metastasis from gastric cancer has not yet been
established. In this study, we evaluated the efficacy of hepatic arterial infusion for synchronous
hepatic metastasis from gastric cancer.
Patients and methods: This study consisted of 37 patients [HAI group; 18 and non-HAI group;
19] with synchronous multiple liver metastases from gastric cancer at Gunma Prefecture Saiseikai-
Maebashi Hospital. We retrospectively analyzed the efficacy of HAI.
Results: Response rate (CR + PR) of HAI was 83%. However, HAI treatment did not affect any
improvement in the survival rate.
Conclusion: HAI is an effective treatment for control of liver metastasis specifically. The factor
effective for an improvement in the survival rate was possibly that of gastrectomy.
Background
The presence of liver metastasis is one of the most impor-
tant prognostic factors in patients with gastrointestinal
cancer. Gastric cancer with liver metastasis is a non-cura-
ble, fatal disease with a 5-year survival of less than 10% [1-
4]. The efficacy of operative resection of liver metastasis
from colorectal cancer has been established [5-7]. How-
ever, the effectiveness of liver resection for metastasis from
gastric cancer remains unknown [8-10]. Generally, these
patients should receive systemic chemotherapy apart from
surgical resection. Some new active anticancer drugs and
effective combination regimens have been reported [11-
14]. As one of the critical factors determining prognosis is
liver metastasis, local control is considered most impor-
tant.
Recently, advances in vascular interventional radiology
have made it easier to insert a catheter percutaneously.
Connecting a catheter indwelling in the hepatic artery
with a subcutaneously implanted port system facilitates
repeated hepatic arterial infusion (HAI) on an outpatient
basis [15]. Hepatic metastasis of gastric cancer might pos-
sibly be controlled as easily as that of colorectal cancer.
However, the development of extrahepatic lesions during
HAI therapy could be an important factor determining
prognosis [16]. We evaluated the efficacy of hepatic arte-
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rial infusion for synchronous hepatic metastasis from gas-
tric cancer.
Methods
This study consisted of 37 patients (30 (81%) males and
7 (19 %) females; mean age 70.5 ± 8.5 years; range, 54 to
85 years) who had all undergone treatment for synchro-
nous multiple liver metastases from gastric cancer
between January 1, 1996 and December 31, 2004 at
Gunma Prefecture Saiseikai-Maebashi Hospital.
HAI was performed in our hospital from April, 2001. Our
treatment policy for gastric cancer with multiple liver
metastases is first to operate on the primary lesion and
then HAI is instituted. We perform gastrectomy to main-
tain QOL if the performance status is good. However, nei-
ther an operation nor HAI can sometimes be undertaken.
The reasons for which operations were not performed for
the study patients were as follows; aged over 85 years (4
patients), and peritonitis carcinomatosa with ascites, Vir-
chow metastasis, multiple lung metastasis, and did not
agree to an operation (one each). 18 patients underwent
hepatic arterial infusion (HAI) of 5-fluorouracil (5-FU).
The remaining 19 patients underwent other treatments,
excepting HAI, or were not treated. The reasons for which
we did not perform HAI were as follows; 15 patients were
cases seen before April, 2001, while in 4 patients the inser-
tion of a catheter was impossible for various reasons. Fif-
teen patients underwent systemic chemotherapy with
tegafur (2 cases), 5-Fluorouracil/cisplatin (5-FU/CDDP)
(10 patients) or S-1 (3 patients). Four of the remaining
patients were not treated because they were 85 years or
older. HAI was performed by repeated HAI chemotherapy
employing an implantable port system. The right gastric
artery and posterior superior pancreatico duodenal artery
were embolized with a metal coil and a catheter inserted
from the right femoral artery with its tip located in the gas-
troduodenal artery. We made a side entrance on the cath-
eter that was opened from the tip for about 3 cm. The side
entrance was located in the proper hepatic artery. When
gastrectomy was performed, embolization of the right gas-
tric artery was omitted. An arterial implantable port was
inserted subcutaneously in the thigh. The regimen was as
follows: 5-FU (once 500 mg/body week for 2 hours). CT
of the liver was obtained every 3 months, and efficacy was
evaluated as complete response (CR), partial response
(PR), no change (NC) and progressive disease (PD). HAI
was continued if the evaluation after three months
showed it to be effective. HAI was essentially undertaken
on an outpatient basis. All patients had synchronous and
multiple liver metastases from gastric cancer; we excluded
metachronous and/or single liver metastasis from gastric
cancer. Therefore, there were no adjustments for resection
of the liver. One patient survived for more than 5 years
without any signs of recurrence.
Survival was analyzed by the Kaplan-Meier method. Mul-
tivariate analysis was performed by the log-rank test and
statistical significance was determined by P < 0.05.
Results
Table 1 presents the patient characteristics. There were dif-
ferences in the depth of invasion between the two groups.
All in the HAI group and 11 (58%) in the non-HAI group
had undergone gastrectomy. The diameters of liver metas-
tases in the HAI group were significantly smaller than
those in the non-HAI. The median survival time (MST)
was 19.2 months in the HAI group and 8.8 months in the
non-HAI. There were no significant differences between
the two groups.
Table 2 shows the response to HAI. Fifteen patients (83%)
in the responding group showed good outcomes (CR,
PR), while 3 (17%) in the non-responding group showed
bad outcomes (NC, PD). There were no significant differ-
ences between the two groups in regard to pathology and
diameter of liver metastasis. The duration of response in
the responding group was 11.4 months. However, the
duration of response in the responding group, except for
Table 1: Characteristics of patients
HAI non-HAI p-value
n1 8 1 9
Age 65.9 ± 6.1 73.6 ± 10.2 0.1882
Gender M/F 17/1 13/6 0.0518
Depth of invasion
T1 1 0
T2 10 2 0.0111
T3 3 9
T4 4 2
Unknown 0 6
Lymphnode metastasis
N0 3 0
N1 8 4 0.2486
N2 4 6
N3 3 1
Unknown 0 8
Location
U5 1
M 10 14 0.1422
L3 4
Operation
+ 18 11 0.0024
-0 8
Metastasis
lung 2 1
Virchow 1 1 0.8281
peritoneum 2 1
other 1 0
Diameter of Liver metastasis 
(cm)
5.8 ± 1.9 7.7 ± 3.7 0.04137
Median survival (mon) 19.2 8.8 0.09596World Journal of Surgical Oncology 2007, 5:70 http://www.wjso.com/content/5/1/70
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one case who has survived for over 5 years, was 7.6
months. MST was 20.0 months in the responding group
and 15.3 in non-responding group.
Multivariate analysis indicated that HAI therapy was an
independent prognostic factor that influenced survival (p
= 0.0120). However, except for the one case who survived
for over 5 years, it was not an independent prognostic fac-
tor influencing survival (p = 0.0911). Other chemothera-
pies did not significantly contribute to prognosis (p =
0.9460).
Figure 1 shows a Kaplan-Meier survival curve. MST in the
HAI group was 19.2 months and MST in the non-HAI
group was 8.8 months; a more than two-fold difference
that was, however, not significant (p = 0.09596). One
patient in the HAI group survived for more than 5 years.
Figure 2 shows a Kaplan-Meier survival curve taking into
account gastrectomy. Although all patients in the HAI
group underwent gastrectomy, 8 patients (42%) in the
non-HAI group did not undergo gastrectomy. Therefore,
we examined the survival rate of the patients who had
undergone gastrectomy. The survival curves from each
group were found to correspond; therefore, the overall
reduced survival rate in the non-HAI group shown in Fig-
ure 1 was considered to due to the patients without gast-
rectomy.
Discussion
The prognosis for advanced gastric cancer has remained
poor despite recent developments in chemotherapy.
Although anti-cancer drugs are mainly administered intra-
venously, HAI is also performed [17-21]. HAI is not a sys-
temic treatment but is an effective treatment for local
organ providing a higher concentration to the tumor tis-
sue and a lower one in the rest of the body. Therefore, HAI
is expected to produce decreased side effects. The recurring
type of advanced gastric cancer is complex and many cases
of advanced gastric cancer have relapsed because of the
combination of peritoneal dissemination, liver metastasis
and/or lymph node metastasis. Local control, especially
liver control, may be the most important strategy to
extend survival. There are various HAI chemotherapy reg-
imens. Several use a high dose of 5-FU and/or a combina-
tion of two or more anticancer drugs. In this study, the
amount of 5-FU used was not so much, which enabled
HAI to be continued for a long period. Although we did
attempt to perform HAI chemotherapy with a high dose of
5-FU, we found we could not continue chemotherapy
because of strictures and/or degeneration of the hepatic
artery. Therefore, we selected a lower dose (see Methods).
In this study, there were no severe side effects and the aver-
age period of HAI was 14.7 months. The MST of the HAI
group was 19.2 months, thus HAI was used for a long
period without side effects being demonstrated.
Survival curves of patients with multiple liver metastases  from gastric cancer who underwent gastrectomy Figure 2
Survival curves of patients with multiple liver metastases 
from gastric cancer who underwent gastrectomy.
Table 2: response of HAI
respondin
g group
CR, PR
non-responding 
group
NC, PD
p-value
n1 5 3
Pathology
differentiated 10 3 0.2393
undifferentiated 5 0
Diameter of tumor (cm) 6.1 ± 1.9* 4.3 ± 3.2* 0.2099
Other metastasis 5 1
Duration of response in all 
patients (mon)
11.4
Duration of response (mon) 7.6
(except one case who 
survive over 5 years)
Median survival (mon) 20.0 15.3
*: AVG ± SD
Survival curves of patients with synchronous and multiple  liver metastases from gastric cancer Figure 1
Survival curves of patients with synchronous and multiple 
liver metastases from gastric cancer.World Journal of Surgical Oncology 2007, 5:70 http://www.wjso.com/content/5/1/70
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Although the overall response (CR + PR) rate was 83%,
survival rate not extended. This response rate may be asso-
ciated with an improvement of QOL; however, we did not
evaluate the effect of HAI on QOL in this study so investi-
gation is needed to evaluate the relationship. The progno-
sis of cases that underwent gastrectomy was good; that is,
cases that could undergo gastrectomy achieved a good
prognosis. The magnitude of the improvement in survival
did not depend on HAI chemotherapy, the most impor-
tant factor was the state of the patient.
Conclusion
HAI is an effective treatment to control liver metastasis on
its own. Local benefits to the liver were obtained by per-
forming HAI for a long period of time, and the amount of
5-FU of 500 mg was an appropriate quantity. HAI was not
associated with any improvement in the survival rate,
which was conditional on the possibility of gastrectomy.
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